Skip to main content
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: Lung Cancer. 2017 Jun 8;110:42–47. doi: 10.1016/j.lungcan.2017.06.002

Table 2.

Lung cancer incidence by randomization group in the WHI CaD Trial over the cumulative follow-up period*

CaD Placebo
No. cases (% per year)		 CaD intervention
No. cases (% per year)		 HR (95%CI)a
Lung cancer incidence 241 (0.12) 207 (0.11) 0.91 (0.71–1.17)
 SCLC 21 (0.01) 25 (0.01) 1.44 (0.64–3.25)
 NSCLC 220 (0.09) 182 (0.10) 0.87 (0.67–1.27)
  Squamous cell 31 (0.02) 38 (0.02) 1.65 (0.91–2.97)
  Adenocarcinoma 118 (0.06) 85 (0.04) 0.71 (0.49–1.04)
*

HR: hazard ratios; CI: confidence interval; SCLC: small cell lung cancer; NSCLC: non-small cell lung cancer.

a

The HRs and 95% CIs for the overall combined periods events adjusted by age, HT and DM randomization arm, smoking status, pack-years of smoking, and trial phase (time dependent).